Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTX
Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Turning Point Therapeutics, Inc. Buyout
Turning Point Therapeutics' Shares Soar on Bristol-Myers Squibb Deal
SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.
Here is Why Turning Point Therapeutics Jumped 110%
Turning Point Therapeutics shares more than doubled on Friday
TPTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Turning Point Therapeutics, Inc. Is Fair to Shareholders
TPTX Stock Soars 115% as Bristol Myers Announces Takeover of Turning Point Therapeutics
Turning Point Stock Doubles After Bristol Myers Announces Takeover
Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal
Turning Point Therapeutics stock more than doubles after Bristol Myers buyout deal valuing company at $3.8 billion
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
Is Turning Point Therapeutics Stock at a Turning Point?
Best Biotech Stocks To Buy Now? 5 To Know
Turning Point Therapeutics to Participate in Upcoming Investor Conferences
What Makes Turning Point Therapeutics (TPTX) a New Buy Stock
FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q3 2021 Results - Earnings Call Transcript
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
Turning Point Therapeutics to Participate In Upcoming Investor Conferences
Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors
Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q2 2021 Results - Earnings Call Transcript
Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q1 2021 Results - Earnings Call Transcript
Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates
Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting
Turning Point Therapeutics, Inc. (TPTX) CEO Athena Countouriotis on Q4 2020 Results - Earnings Call Transcript
Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates
Why Turning Point Is Turning Heads
Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call
5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty
3 Companies With High Quality Balance Sheets to Consider
Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer